Aparnar Parikh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

<p>In a study led by investigators from <a href="https://www.massgeneralbrigham.org/" target="_blank">Mass General Brigham</a>, <a href="https://wyss.harvard.edu/" target="_blank">the Wyss Institute for Biologically Inspired Engineering at Harvard University</a> and <a href="https://www.dana-farber.org/" target="_blank">Dana-Farber Cancer Institute</a>, in collaboration with researchers from across the country and beyond the U.S., researchers developed a low-cost, ultrasensitive blood test to ...

CAMBRIDGE, Mass., April 8, 2022 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., (SMP Oncology) a clinical-stage company focused on research and de...

A recurrence occurs when cancer comes back after treatment. This can happen weeks, months, or even years after the primary or original cancer was treated. It is impossible to know for sure if the cancer will recur and timely detection of recurrence, as well as identification of patients at high risk of recurrence after surgery, can be challenging.  Postsurgical circulating tumor DNA (ctDNA) analysis is a promising tool for the identification of patients with minimal residual disease. Now researchers at Massachusetts General Hospital (MGH) report they have evaluated the first test that detect...

Novel Test Detects Leftover Cancer DNA in the Blood by Angela Mohan on  April 30, 2021 at 2:59 PM Tumor-uninformed test detects the residual or leftover cancer DNA circulating in the blood of patients following treatment. Guardant Reveal test developed by precision oncology company Guardant Health, is "tumor-uninformed". It doesn't require knowing mutations that were present in the patient's tumor. "The use of ctDNA, which is a type of 'liquid biopsy', is a powerful prognostic tool to detect residual disease, and many prospective trials are under way in the United States, E...

Study evaluates first tumor-uninformed ctDNA assay to detect residual cancer cells after treatment After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence. Non-invasive tools to detect microscopic disease are of especially high value. In a new study published in Clinical Cancer Research a team led by investigators at Massachusetts General Hospital (MGH) has evaluated the first "tumor-uninformed" test that detects cancer DNA circulating in the blood of patients following treatment. Th...